Vor Biopharma (VOR) Return on Capital Employed (2021 - 2026)
Vor Biopharma (VOR) reported Return on Capital Employed of 79.58% for Q1 2026, up 3210.0% year-over-year from 2.4% in Q1 2025, and up 36.83% on a QoQ basis from 125.98% in Q4 2025.
Vor Biopharma (VOR) has 6 years of Return on Capital Employed data on file, last reported at 79.58% in Q1 2026.
- Quarterly Return on Capital Employed rose 3210.0% year-over-year to 79.58% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79.58% (up 3210.0% YoY) and the FY2025 annual result came in at 133.52%, down 5374.0% from the prior year.
- Return on Capital Employed advanced to 79.58% in Q1 2026 per VOR's latest filing, from 125.98% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.45% in Q1 2022 and bottomed at 372.73% in Q2 2025.
- The 5-year median for Return on Capital Employed is 75.54% (2024), against an average of 96.21%.
- The widest annual swing landed in 2025, when Return on Capital Employed sank 28391 bps; it then soared 3210 bps in 2026.
- Tracing VOR's Return on Capital Employed over 5 years: stood at 38.96% in 2022, then tumbled by 66 bps to 64.63% in 2023, then tumbled by 69 bps to 109.34% in 2024, then fell by 15 bps to 125.98% in 2025, then surged by 37 bps to 79.58% in 2026.
- Per Business Quant, the three latest VOR Return on Capital Employed figures stand at 79.58% (Q1 2026), 125.98% (Q4 2025), and 213.41% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -79.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.58% |
| Dec 31, 2025 | -125.98% |
| Sep 30, 2025 | -213.41% |
| Jun 30, 2025 | -372.73% |
| Mar 31, 2025 | -111.68% |
| Dec 31, 2024 | -109.34% |
| Sep 30, 2024 | -103.10% |
| Jun 30, 2024 | -88.82% |
| Mar 31, 2024 | -75.54% |
| Dec 31, 2023 | -64.63% |
| Sep 30, 2023 | -55.34% |
| Jun 30, 2023 | -44.30% |
| Mar 31, 2023 | -36.63% |
| Dec 31, 2022 | -38.96% |
| Sep 30, 2022 | -42.56% |
| Jun 30, 2022 | -37.53% |
| Mar 31, 2022 | -35.45% |
| Dec 31, 2021 | -28.70% |
| Sep 30, 2021 | -25.76% |
| Jun 30, 2021 | -21.60% |
| Mar 31, 2021 | -28.00% |